2-氨基-4-羟基蝶啶-6-甲醛 | 712-30-1

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 中文名称: 2-氨基-4-羟基蝶啶-6-甲醛
• 中文别名: 2-氨基-4-氧代-3,4-二氢蝶啶-6-甲醛
• 英文名称: 6-formyl-pterin
• 英文别名: 2-Amino-4-hydroxy-6-formylpteridine；2-amino-4-oxo-3H-pteridine-6-carbaldehyde
• CAS: 712-30-1
• 化学式: C₇H₅N₅O₂
• mdl: MFCD00160709
• 分子量: 191.149
• InChiKey: LLJAQDVNMGLRBD-UHFFFAOYSA-N

物化性质

• 熔点：
  280 °C (decomp)
• 沸点：
  398.6±52.0 °C(Predicted)
• 密度：
  1.94±0.1 g/cm3(Predicted)
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090
• 储存条件：
  -20°C，惰性气体

制备方法与用途

6-Formylpterin 是一种Xanthine Oxidase的抑制剂，并能诱导HL-60细胞内ROS生成及细胞凋亡。此外，6-Formylpterin 还能够抑制PanC-1细胞的增殖。

反应信息

• 作为反应物：
  描述：

  2-氨基-4-羟基蝶啶-6-甲醛 在 tyrosinase 作用下， 生成 2-氨基-4-羟基蝶啶
  参考文献：
  名称：

  Photoinactivation of tyrosinase sensitized by folic acid photoproducts

  摘要：

  Tyrosinase catalyzes in mammals the first and rate-limiting step in the biosynthesis of the melanin, the main pigment of the skin. Pterins, heterocyclic compounds able to photoinduce oxidation of biomolecules, accumulate in the skin of patients suffering from vitiligo, where there is a lack of melanin. Folic acid (PteGlu) is a conjugated pterin widespread in biological systems. Aqueous solutions of tyrosinase were exposed to UV-A irradiation (350 nm) in the presence of PteGlu and its photoproducts (6-formylpterin and 6-carboxypterin). The reactions were followed by UV-Vis spectrophotometry, enzyme activity measurement, fluorescence spectroscopy and HPLC. In this work, we present data that demonstrate unequivocally that solutions of tyrosinase exposed to UV-A irradiation in the presence of PteGlu, undergo enzyme inactivation. However, PteGlu itself causes a negligible effect on the activity of the enzyme. In contrast, PteGlu photoproducts are efficient photosensitizers. The tyrosinase inactivation involves two different pathways: (i) a photosensitization process and (ii) the oxidation of the enzyme by the hydrogen peroxide produced during the photooxidation of PteGlu and its photoproduct. The former pathway affects both the active site and the tryptophan residues, whereas the latter affects only the active site. The biological implications of the results are discussed. (C) 2015 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.jphotobiol.2015.06.002
• 作为产物：
  描述：

  folate 在 氧气 作用下， 以 水 为溶剂， 生成 2-氨基-4-羟基蝶啶-6-甲醛
  参考文献：
  名称：

  蝶呤杂质对市售叶酸的荧光和光化学的影响。

  摘要：

  叶酸或蝶氨-1-谷氨酸（PteGlu）是一种共轭蝶呤衍生物，可在膳食中用作叶酸的来源，叶酸是人类多种生理功能所必需的一组化合物。PteGlu的光化学很重要，因为叶酸不是由哺乳动物合成的，会经历光降解，其缺乏与许多疾病有关。我们已经证明，通常的商业PteGlu不能通过未结合的氧化蝶呤6-甲酰基蝶呤（Fop）和6-羧基蝶呤（Cap）纯化。这些化合物的含量如此之低，以致于正常的色谱对照无法检测到任何蝶形污染。但是，PteGlu溶液的荧光是由于Fop和Cap的发射引起的，而PteGlu发射的贡献要低得多，可以忽略不计。这是因为与Fop和Cap的ΦF相比，PteGlu的荧光量子产率（ΦF）非常弱。同样，PteGlu在UV-A辐射下的光降解是一种通过溶液中存在的氧化未结合的蝶呤对光敏化的氧化，而不是由PteGlu直接吸收光子引发的过程。简而言之，使用市售固体制备的PteGlu溶液的荧光和光化学性质是由

  DOI：

  10.1016/j.jphotobiol.2018.03.007
• 作为试剂：
  描述：

  2-(1,3-二氢-3-氧代-5-磺基-2H-吲哚-2-亚基)-3-氧代吲哚啉-5-磺酸 在 2-氨基-4-羟基蝶啶-6-甲醛 、 L-组氨酸 作用下， 反应 0.08h， 生成 靛红-5-磺酸
  参考文献：
  名称：

  Highly sensitive and selective bioluminescence based ozone probes and their applications to detect ambient ozone

  摘要：

  高度选择性和敏感的生物发光臭氧探针已经被开发并应用于测量环境样品中的臭氧浓度。

  DOI：

  10.1039/c5cc08622a

文献信息

• Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
  申请人：Garvey S. David

  公开号：US20050059655A1

  公开（公告）日：2005-03-17

  The invention describes novel nitrosated and/or nitrosylated diuretic compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated diuretic compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one diuretic compound of the invention, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; and (l) treating nephropathy.

  该发明描述了新颖的亚硝基化和/或亚硝酰化利尿化合物或其药用盐，以及包含至少一种亚硝基化和/或亚硝酰化利尿化合物的新型组合物，以及可选地至少一种一氧化氮供体和/或至少一种治疗剂。该发明还提供了包含该发明中至少一种利尿化合物的新型组合物和试剂盒，该利尿化合物可选择地亚硝基化和/或亚硝酰化，并且可选地至少一种一氧化氮供体化合物和/或至少一种治疗剂。该发明还提供了用于(a)治疗由于过多水分和/或电解贮留引起的疾病；(b)治疗心血管疾病；(c)治疗肾血管疾病；(d)治疗糖尿病；(e)治疗由氧化应激引起的疾病；(f)治疗内皮功能障碍；(g)治疗由内皮功能障碍引起的疾病；(h)治疗肝硬化；(j)治疗子痫前期；(k)治疗骨质疏松症；和(l)治疗肾病的方法。
• Nitric oxide enhancing diuretic compounds, compositions and methods of use
  申请人：Garvey S. David

  公开号：US20060189603A1

  公开（公告）日：2006-08-24

  The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia. The nitric oxide enhancing diuretic compounds comprise at least one nitric oxide enhancing group linked to the diuretic compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed.

  该发明描述了包含至少一种增强一氧化氮利尿化合物或其药用盐的新型组合物和试剂盒，以及可选地，至少一种增强一氧化氮化合物和/或至少一种治疗剂的试剂盒。该发明还提供了以下方法：(a)治疗由过多水分和/或电解贮留引起的症状；(b)治疗心血管疾病；(c)治疗肾血管疾病；(d)治疗糖尿病；(e)治疗由氧化应激引起的疾病；(f)治疗内皮功能障碍；(g)治疗由内皮功能障碍引起的疾病；(h)治疗肝硬化；(j)治疗子痫前期；(k)治疗骨质疏松症；(l)治疗肾病；(m)治疗外周血管疾病；(n)治疗门静脉高压；(o)治疗中枢神经系统疾病；(p)治疗代谢综合征；(q)治疗性功能障碍；以及(r)高脂血症。增强一氧化氮利尿化合物包括至少一种增强一氧化氮基团，通过碳、氧和/或氮等一个或多个位点与利尿化合物连接，连接通过不能水解的键或基团。
• [EN] NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE<br/>[FR] COMPOSÉ D'ESTER D'ACIDE AMINÉ LIBÉRANT UN OXYDE NITRIQUE, COMPOSITION ET  PROCÉDÉ D'UTILISATION
  申请人：ORAL DELIVERY TECHNOLOGY LTD

  公开号：WO2010034118A1

  公开（公告）日：2010-04-01

  There is provided amino acid ester compounds comprising at least one nitric oxide releasing group, pharmaceutically acceptable salts thereof and compositions thereof. These compounds involve an amino acid side-chain or an amino acid derivative thereof and a nitric oxide releasing group as depicted in the following structures: wherein R1 is either an ethyl or an amino acid side-chain group or an amino acid derivative thereof and R2 is an amino acid side-chain group or an amino acid derivative thereof and n is an integer from 1 to 10.

  提供的氨基酸酯化合物包括至少一个释放一氧化氮基团的化合物，其药学上可接受的盐和组合物。这些化合物涉及氨基酸侧链或其衍生物以及释放一氧化氮基团，如下面的结构所示：其中R1是乙基或氨基酸侧链基团或其衍生物，R2是氨基酸侧链基团或其衍生物，n是从1到10的整数。
• [EN] POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À DES EXCIPIENTS POLYMÉRIQUES HYPERBRANCHÉS
  申请人：ASCENDIS PHARMA AS

  公开号：WO2013024048A1

  公开（公告）日：2013-02-21

  The present invention relates to water-soluble carrier-linked prodrugs of formula (I),wherein POL is a polymeric moiety,each Hyp is independently a hyperbranched moiety,each moiety SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, m is 0 or 1, each n is independently an integer from 2 to 200 and each x is independently 0 or 1. It further relates to pharmaceutical compositions comprising said water- soluble carrier-linked prodrugs and methods of treatment.

  本发明涉及水溶性载体连接的前药，其化学式为（I），其中POL是聚合物基团，每个Hyp是独立的超支化基团，每个基团SP是独立的间隔基团，每个L是独立的可逆前药连接基团，m为0或1，每个n是独立的整数，范围从2到200，每个x是独立的0或1。此外，还涉及包含所述水溶性载体连接的前药的药物组合物和治疗方法。
• [EN] HIGH-LOADING WATER-SOLUBLE CARRIER-LINKED PRODRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À DES EXCIPIENTS HYDROSOLUBLES DE FORTE CHARGE
  申请人：ASCENDIS PHARMA AS

  公开号：WO2013024047A1

  公开（公告）日：2013-02-21

  The present invention relates to water-soluble carrier-linked prodrugs of formula (I), wherein B, A and Hyp form the carrier, B is a branching core, each A is independently a poly(ethylene glycol)-based polymeric chain, each Hyp is independently a branched moiety, each SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, each D is independendly a biologically active moiety, each x is independently 0 or 1, each m is independently an integer of from 2 to 64, n is an integer from 3 to 32; or the pharmaceutically acceptable salt thereof. It further relates to pharmaceutical compositions comprising said water-soluble carrier-linked prodrugs, their use asmedicament or diagnostic, and methods of treatment.

  本发明涉及水溶性载体连接的前药，其化学式为(I)，其中B、A和Hyp形成载体，B是一个分支核心，每个A独立地是一条聚乙二醇基聚合链，每个Hyp独立地是一个分支基团，每个SP独立地是一个间隔基团，每个L独立地是一个可逆前药连接基团，每个D独立地是一个生物活性基团，每个x独立地为0或1，每个m独立地是从2到64的整数，n是从3到32的整数；或其药学上可接受的盐。进一步涉及包括所述水溶性载体连接的前药的药物组合物，其用作药物或诊断，以及治疗方法。